Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - AccuredReceivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Kura Oncology (KURA) Shares Outstanding (2022 - 2026)

Kura Oncology has reported Shares Outstanding over the past 5 years, most recently at $88.8 million for Q1 2026.

  • Quarterly Shares Outstanding rose 9.89% to $88.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $88.8 million through Mar 2026, up 9.89% year-over-year, with the annual reading at $87.9 million for FY2025, 12.3% up from the prior year.
  • Shares Outstanding was $88.8 million for Q1 2026 at Kura Oncology, up from $87.9 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $88.8 million in Q1 2026 and troughed at $68.3 million in Q4 2022.
  • The 5-year median for Shares Outstanding is $77.1 million (2024), against an average of $78.5 million.
  • Year-over-year, Shares Outstanding rose 3.07% in 2024 and then rose 13.58% in 2025.
  • A 5-year view of Shares Outstanding shows it stood at $68.3 million in 2022, then increased by 8.84% to $74.4 million in 2023, then rose by 5.22% to $78.2 million in 2024, then rose by 12.3% to $87.9 million in 2025, then grew by 1.03% to $88.8 million in 2026.
  • Per Business Quant, the three most recent readings for KURA's Shares Outstanding are $88.8 million (Q1 2026), $87.9 million (Q4 2025), and $87.0 million (Q3 2025).